Celldex Therapeutics, Inc. (NASDAQ:CLDX) Records Rapid Fluctuations Amid Long Silence

0
839

Celldex Therapeutics, Inc. (NASDAQ:CLDX) has been fluctuating in the stock market, for the last 2-months, but has recorded an overall decline in its share value. The stock is currently trading at $3.28 per share, as compared to $3.54 per share, at the beginning of March 2017. One of the main reasons for this trend is the fact that the company has been silent, since having issued a corporate update and FY2016 financial results, on March 15, 2017. It is expected that the stock would remain volatile for the near future.

In its last press release, the CEO of the company, Anthony Marucci, claimed that CLDX has made significant progress with its pipeline, during the 4Q2016, including the successful integration of Kolltan Pharmaceuticals and its RTK antibody programs. He further claimed that the company experienced a significant uptick in the enrollment of patients, in clinical studies. The CEO further stated that for the FY2017, their main priority would be completing the glemba studies, for triple negative breast cancer and metastatic melanoma. Data from these studies is expected to be made available, in the next 6-12 months.

Added to this, Celldex is also expected to undergo a change in management, during the summer of 2017, as the company’s CFO and Senior VP, Chip Catlin, has expressed his intention to retire. Mr. Marucci has stated that the management has decided to replace him with Sam Martin, the current VP of finance. He claimed that the transition is expected to be seamless, given that the two have been working closely, for the last 8-years.

Regarding its financial health, CLDX revealed that as of December 31, 2106 it has a cash position of $189.8 million, as compared to $203.2 million, three months ago. The company noted that it has spent an estimated $20.3 million, for its operating activities, during the 4Q2016 alone. Revenues for the period stood at $1.9 million, only slightly higher than the preceding year. However, CLDX’s R&D expenses recorded a surge of approximately $0.7 million, during the same period.

This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.